Breaking news

Wispr Flow Redefines AI Dictation With Strategic Funding and Global Ambitions

by THEFUTURE.TEAM

November 20, 2025

Wispr, an innovator in the voice AI sector, is rapidly establishing its presence with its flagship dictation app, Wispr Flow. Early usage statistics reveal that after just three months, an average user dictates more than half of all their characters through the app. Moreover, the startup has successfully penetrated the Fortune 500 ecosystem, engaging 270 industry giants and securing 125 enterprise partnerships.

Robust Funding and Strategic Board Developments

The company’s upward trajectory is accentuated by significant capital injections. Following a $30 million round led by Menlo Ventures in June, Wispr has raised an additional $25 million in a round spearheaded by Notable Capital, with participation from Steven Bartlett’s Flight Fund. This latest infusion brings Wispr’s total funding to $81 million. Notably, Notable’s Hans Tung—whose investment portfolio includes Affirm, Airbnb, Slack, Coinbase, Anthropic, and TikTok—is now on board as an observer, reflecting high-level confidence in the company’s vision.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Compelling Growth Metrics and User Engagement

Wispr’s CEO, Tanay Kothari, highlighted that Wispr Flow has experienced an impressive 40% month-over-month growth since June. The dictation platform has also enjoyed remarkable adoption within the venture capital community, attracting substantial inbound interest from investors. Kothari noted, “We were not planning a raise due to our long runway and lean team, but when the opportunity arose with Hans and Steven, it aligned perfectly with our strategic roadmap.”

Strategic Enhancements and International Expansion

In addition to solid user growth—evidenced by a 100x year-over-year increase and a 70% retention rate over 12 months—Wispr is actively addressing early challenges. Initially, non-technical users struggled to fully utilize the app’s capabilities beyond the built-in dictation feature. In response, the company introduced a refined user onboarding flow that directs users to apply dictation across their most-used apps. Furthermore, while the platform is currently available on Windows, Mac, and iOS, Wispr is set to launch a beta Android version by year-end, with a full release planned for Q1 2025.

Advancing Technology With AI and Automation

Wispr is now investing in the development of proprietary voice models to deliver personalized Automatic Speech Recognition (ASR), aiming to lower the need for post-dictation edits. The company boasts an error rate of around 10%, significantly outperforming alternatives such as OpenAI’s Whisper at 27% and Apple’s native transcription at 47%. Beyond dictation, Wispr envisions its app evolving into a voice-led operating system capable of automating tasks such as email responses.

Market Position Amidst Growing Competition

Even as venture capital interest surges, Wispr faces competition from emerging contenders like YC-backed Willow, Aqua, and Monologue among others. Nonetheless, industry leaders have noted Wispr Flow’s seamless user experience and robust design as key differentiators in a crowded market.

Looking Ahead

Kothari remains optimistic about the company’s future, with plans to fuel international growth and explore new product opportunities. The recent funding round promises to secure top-tier machine learning talent, ensuring that Wispr remains at the forefront of the AI dictation revolution.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.